Zacks Investment Research Lowers ArQule, Inc. (ARQL) to Hold
ArQule, Inc. (NASDAQ:ARQL) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday.
According to Zacks, “ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule’s lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company’s lead ACT program, based on the E2F-1 pathway, is partnered with Roche. “
Separately, ValuEngine downgraded shares of ArQule from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.
ArQule (NASDAQ ARQL) traded down 4.46% during mid-day trading on Tuesday, hitting $1.07. 98,149 shares of the stock traded hands. The stock has a 50 day moving average price of $1.12 and a 200 day moving average price of $1.12. ArQule has a 12-month low of $0.92 and a 12-month high of $1.68. The firm’s market cap is $76.15 million.
ArQule (NASDAQ:ARQL) last released its earnings results on Friday, August 4th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01. During the same quarter in the previous year, the company earned ($0.07) earnings per share. On average, analysts expect that ArQule will post ($0.43) earnings per share for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in the company. Curbstone Financial Management Corp increased its position in shares of ArQule by 100.0% in the third quarter. Curbstone Financial Management Corp now owns 104,572 shares of the biotechnology company’s stock worth $116,000 after acquiring an additional 52,286 shares in the last quarter. Northern Trust Corp increased its position in shares of ArQule by 0.9% in the second quarter. Northern Trust Corp now owns 154,513 shares of the biotechnology company’s stock worth $192,000 after acquiring an additional 1,385 shares in the last quarter. Finally, First Eagle Investment Management LLC increased its position in shares of ArQule by 8.6% in the second quarter. First Eagle Investment Management LLC now owns 11,847,575 shares of the biotechnology company’s stock worth $14,691,000 after acquiring an additional 934,842 shares in the last quarter. 61.03% of the stock is currently owned by institutional investors and hedge funds.
ArQule Company Profile
ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ArQule Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule Inc. and related companies with MarketBeat.com's FREE daily email newsletter.